

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE**  
**MINUTES from 27<sup>th</sup> September 2018**

**Present:**

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – ( APC Chair)	✓	Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Richard Harris – LPC Representative	✓
Mr Alex Molyneux - Head of Medicines Management (NHSD-MMT)		Mr Andrew Houston - Senior Mental Health Pharmacist		Mr P Chatterton - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)	✓			<u>DBTHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Mrs Heidi Atkinson- Non Medical Prescriber Representative (RDaSH DCIS)		Mr Andrew Barker – Chief Pharmacist DBTHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBTHFT	✓
Mr Rob Wise – APC Deputy Chair Head of Medicines Management (BCCG)	✓	<u>Doncaster LMC</u>		Dr Lucy Peart – Acute Physician DBTHFT	✓
		Dr Dean Eggitt - LMC Secretary		Mr John Bane – Deputy Chief Pharmacist DBTHFT	
		Dr Runit Shah – LMC Chair	✓	<u>FCMS</u>	
				Mrs Amanda Thompson Mrs Nicola Sanders Mrs Alison O’Conner Mrs Annie Armitage Mr Andrew Shakesby	

**Minutes Only: Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee**

**Dr Rupert Suckling & Mr Victor Joseph DMBC**

**In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)**

<b>Agenda Item</b>	<b>Discussion Points</b>	<b>Action By</b>
09/18/1	<b>Apologies</b> Apologies were received from Mr Alex Molyneux, FCMS & Mr J Bane	
09/18/2	<b>Declarations of Interest, Gifts or Hospitality</b> No declarations were received	

09/18/3	<p><b>Minutes of last meeting</b></p> <p>The minutes of the last meeting held on the 30<sup>th</sup> August 2018 were agreed as a true and accurate record and will be made available on the medicines management website.</p>	NHSD-MMT(AM)
09/18/4.1	<p><b>Matters Arising</b></p>	
10/17/8.1	<p><b>FreeStyle Libre (FSL) Glucose Monitoring System</b></p> <p>A meeting with DCCG, DBTHFT and RDaSHFT is due to take place later today. The business case and pathway of care will be discussed. DCCG has received a letter from Secondary Care in Sheffield regarding the availability of the FSL system for Doncaster patients prescribed the system out of area. A response will be prepared following the meeting.</p> <p>Feedback will be brought back to the October meeting.</p>	NHSD-MMT(GB)
11/17/19.2	<p><b>Methotrexate injections –change from Red to Amber on TLS</b></p> <p>DBTHFT has confirmed that the Rheumatology Department has agreed to process the referral to the waste disposal service. The paperwork should be ready for approval at the October APC meeting.</p>	NHSD-MMT(GB)
06/18/8.1	<p><b>Bicalutamide: Amber G (current status) vs Amber</b></p> <p>This Committee has previously sent a request to the urology department to consider developing shared care to support the prescribing of bicalutamine. NHSD-MMT will now speak directly with the department to clarify the reason for the request with them and will feedback at the next meeting.</p>	NHSD-MMT(GB)
06/18/8.2	<p><b>Letrozole - Amber G – monitoring responsibility</b></p> <p>NHSD-MMT has not received a response from DBTHFT regarding the responsibility of arranging the DEXA scan. The plan is to now write to the Head of Service to seek to clarify the process.</p> <p><i>Mr S Davies joined the meeting</i></p>	NHSD-MMT(GB)
09/18/5	<p><b>Traffic Light – Drugs for Review</b></p> <p>All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter.</p> <p>Fosfomycin oral sachets (Monuril) used to treat complicated UTI's remains Green- G  Ospemifene (Senshio) used for moderate to severe vulvar and vaginal atrophy has been categorised as Amber–G, non-formulary  Roflumilast (Daxas) used to treat COPD has been categorised as Amber-G, refer to formulary guidance (from NICE)</p>	NHSD-MMT(AM)

09/18/6	<p><b>APC Officers actions</b> All officers actions were agreed as proposed, will be updated on the traffic light system.</p>	NHSD- MMT(AM)
09/18/7	<p><b>Traffic Light – Additions for Consideration</b> All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter.</p> <p>Axicabtagene (YESCARTA) used to treat lymphoma has been categorised as Red 1,2,3 Dinutuximab (Qarziba) used to treat neuroblastoma has been categorised as Red 1,2 Erenumab (Aimovig) used for the prophylaxis of migraine has been categorised as Red 1,2 Budesonide (Jorveza) used to treat eosinophilic esophagitis has been categorised as Red 1,2 Daunorubicin/cytarabine (Vyxeos) used to treat acute myeloid leukaemia has been categorised as Red 1,2 Nonacog beta pegol (Refixia) used to treat haemophilia B has been categorised as Red 1,2</p>	NHSD- MMT(AM)
09/18/8	<p><b>New Business</b></p>	
09/18/8.1	<p><b>Gluten Free (GF) Food on NHS Prescription in England</b></p> <p>The Committee was advised of a further national consultation on GF foods. The purpose of this consultation is to consider items to be moved on to the NHS drug tariff black list prohibiting prescribing on FP10. The CCG has sent a response to the consultation and this Committee asks that all organisations respond.</p> <p>BCCG advised the Committee of a further local consultation that has been developed by SY&amp;B sICS Medicines Optimisation Work-stream Steering Group; this consultation is around further reductions to prescribing. Each CCG's Governing Body will need to support this before implementation.</p>	
09/18/8.2	<p><b>SCP for Epilepsy in adults</b></p> <p>The revised Sheffield paperwork was approved by the Committee. DBTHFT and RDaSHFT confirmed that both organisations are expecting some women of child bearing potential taking valproate may be referred back into their service. The paperwork will be added to the medicines management website.</p>	NHSD- MMT(AM)
09/18/8.3	<p><b>SCP for Epilepsy in children</b></p> <p>The Committee was asked to comment on the Sheffield SCP document. Following discussion it was agreed that the following should be fed back to Sheffield:</p> <ul style="list-style-type: none"> <li>• The drug classification plus a title should be added to the</li> </ul>	NHSD- MMT(GB)

	<p>columns in the table</p> <ul style="list-style-type: none"> <li>• A flow chart similar to the one in the adult paperwork would be helpful</li> <li>• Clarity around the rationale behind the inclusion of stiripentol and paraldehyde</li> <li>• Reference to the CBNF would be helpful</li> </ul> <p>RDASH FT will obtain comments from the RDASH FT Paediatric Nurse Specialist. NHSD-MMT will feedback these comments for consideration.</p>	RDASH FT
09/18/8.4	<p><b>Terms of Reference (ToR)</b></p> <p>The ToR was reviewed by the Committee. It was agreed to include mention of the traffic light function to section 2.1.3. The membership section also needed to be updated. Following these alterations the document was approved.</p>	NHSD-MMT(AM)
09/18/8.5	<p><b>Use of phrase “Consultant/Specialist Service” within Shared Care Protocol &amp; Proforma paperwork</b></p> <p>A query has come in to NHSD-MMT regarding the sign off on SCP paperwork. Clarification of who could sign the proforma has been requested. Following discussion it was agreed that: The sign off needs to be done by a person with a prescribing qualification and is working within the governance of their department. Both RDaSHFT and DBTHFT have agreed to provide assurance that this is a reflection of the current process.</p> <p>Following this discussion it was agreed that when SCP paperwork is due for review there will be a check to ensure that there is a consistency around the wording of the Specialist i.e. not to use Consultant.</p>	RDaSHFT DBTHFT
09/18/8.6	<p><b>COPD Guidance</b></p> <p>The revised COPD guidance document was presented for information. DBTHFT advised the Committee of discussion within their organisation to make further changes. The document will therefore return to the APC once agreed.</p>	DBTHFT
09/18/9	<p><b>DBTHFT D&amp;TC Update</b></p> <p>The minutes of the meeting held in July 2018 were received by the Committee</p>	
09/18/10	<p><b>Formulary Liaison Group Update</b></p> <p>No minutes available</p>	
09/18/11	<p><b>Doncaster Prisons Drug &amp; Therapeutic Committee</b></p> <p>No minutes available</p>	
09/18/12	<p><b>RDaSH FT &amp; Medicines Management Committee Update</b></p> <p>The minutes of the meeting held in July 2018 were received by the Committee The Chair highlighted that the implications of the NICE</p>	

	guideline(NG97) for dementia has been acknowledged by RDaSHFT and the shared care arrangement will be reviewed to ensure it reflects the guidance.	
09/18/13	<b>Barnsley Area Prescribing Committee Update</b> The minutes of the meeting held in July 2018 were received by the Committee	
09/18/14	<b>Rotherham Medicines Optimisation Group Update</b> No minutes available	
09/18/15	<b>Sheffield Area Prescribing Committee Update</b> No minutes available	
09/18/16	<b>Nottinghamshire Area Prescribing Committee Update</b> The minutes of the meeting held in June 2018 were received by the Committee	
09/18/17	<b>SY&amp; B sICS Medicines Optimisation Work-stream Steering Group</b> No minutes available	
09/18/18	<b>Northern Regional Medicines Optimisation Committee</b> No minutes available	
09/18/19	<p><b>Any Other Business</b></p> <ul style="list-style-type: none"> <li>ADHD Shared Care The Committee received a request from BCCG to amend the monitoring schedule section of the paperwork by adding the responsibility to monitor weight to include a parent or carer. Following discussion it was agreed to leave the paperwork as previously approved.</li> <li>The Committee was made aware of the campaign around the use of over the counter medications. Paperwork for a local consultation will be distributed soon.</li> <li>The recent ruling over the use of Avastin to treat wet age-related macular degeneration (AMD) will be discussed at future APC meetings.</li> </ul>	
09/18/20	<b>Date, time &amp; venue of next meeting</b> 12 noon prompt Thursday 25th October 2018 in Meeting Room 3 Sovereign House	
	<p>12 noon prompt Thursday 29th November 2018 in Meeting Room 3 Sovereign House</p> <p>No meeting in December</p> <p>12 noon prompt Thursday 31st January 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 28th February 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 28th March 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th April 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 30th May 2019 in Meeting Room 3 Sovereign House</p>	

	<p>12 noon prompt Thursday 27th June 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th July 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th August 2019 in Meeting Room 3 Sovereign House</p>	
--	---	--